In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Harmony Biosciences shows significant undervaluation with a current price far below a high-confidence fair value of $86.39, implying upside potential of 144.6%. Strong financial health scores and zero downside risk scenarios underscore stability, while Monte Carlo analysis signals volatility yet a median valuation above the current price. Diverse valuation methods converge on substantial growth opportunity amid low leverage and solid profitability.